t
Allergy Therapeutics plc announced that all resolutions were passed at its General Meeting held on 31 July 2023, including the approval of its annual report and accounts for the year ended 30 June 2022. The votes in favour for the resolutions ranged from 99.27% to 99.75% of the 333,751,545 total votes cast for each resolution.
| Date | 31 Jul 2023 |
| Time | 14:33:58 |
| Category | AGMs and other meetings |
| ID | 7738H |
Allergy Therapeutics plc
("Allergy Therapeutics", the "Company" or the "Group")
Result of General Meeting
31 July 2023: Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that at the General Meeting today, held for the purposes of approving the Company's annual report and accounts for the year ended 30 June 2022 (the "2022 Accounts"), all resolutions were duly passed.
All resolutions were voted on by way of a poll. The results of the poll were as follows:
|
Resolution |
Votes For |
% of votes for |
Votes Against |
% of votes against |
Votes Withheld |
Total votes cast |
|
1. To receive the Directors' report, the consolidated financial statements and the auditors' report of the Company for the year ended 30 June 2022 (the "2022 Accounts") |
332,831,805 |
99.75% |
822,693 |
0.25% |
97,047 |
333,751,545 |
|
2. To approve the Directors' remuneration report, as set out on pages 64 to 72 of the 2022 Accounts |
330,801,478 |
99.27% |
2,443,679 |
0.73% |
506,388 |
333,751,545
|
- ENDS -
For further information, please contact:
Allergy Therapeutics
Manuel Llobet, Chief Executive Officer
Martin Hopcroft, Interim Chief Financial Officer
+44 (0)1903 845 820
Panmure Gordon (Nominated Adviser and Broker)
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
+44 (0)20 7886 2500
Consilium Strategic Communications
Mary-Jane Elliott / David Daley / Davide Salvi
+44 (0)20 3709 5700
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com.